Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review Vouchers: Buyers Beware!

This article was originally published in RPM Report

Executive Summary

The recent series of sales of priority review vouchers at ever-higher prices has transformed what had seemed to be a failed incentive model into a hot topic. However, one key stakeholder is not celebrating the recent developments: the FDA review teams that have to deliver the faster paced reviews continue to have strong reservations about the program.

You may also be interested in...

KaloBios Pledges To Do The Right Thing On Drug Pricing

In an interview, CEO Cameron Durrant said the time was right for KaloBios to outline its pricing strategy as the company looks to emerge from the Martin Shkreli scandal and bankruptcy.

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, FDA Says

Marketing exclusivity may be better way to go, FDA tells GAO, citing workload burdens and lack of evidence that vouchers have incentivized development of new treatments.

Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric

House committee members deliver a fierce, if not terribly substantive, critique of FDA review processes as part of a hearing on Turing and Valeant.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts